Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian CancerBusiness Wire • 09/13/22
Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk SubgroupsBusiness Wire • 09/11/22
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsBusiness Wire • 08/08/22
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 08/01/22
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8Business Wire • 07/20/22
Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8Business Wire • 07/20/22
NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 07/19/22